World J Urol:经直肠超声引导下的经会阴前列腺活检术后感染并发症的风险因子

2020-10-02 AlexYang MedSci原创

最近,有研究人员调查了经直肠超声引导下经会阴前列腺活检术感染并发症的影响因素。

最近,有研究人员调查了经直肠超声引导下经会阴前列腺活检术感染并发症的影响因素。

研究人员对2010年12月至2020年5月经历了经会阴前列腺活检的2192例患者进行了回顾性分析。他们收集了患者的临床特点和并发症发生率数据,并采用单变量和多变量逻辑回归分析经会阴前列腺活检后感染并发症的独立风险因素。研究结果发现,单变量分析表明以下因素与感染并发症相关:糖尿病、细菌性前列腺炎、尿潴留史、尿路感染史、病核数。此外,多变量逻辑分析显示,糖尿病(OR 2.037,95%CI 1.143-3.572,P=0.021)和尿潴留史(OR 2.563,95%CI 1.284-3.901,P=0.013)是经会阴前列腺活检后感染并发症的独立风险因素。

经会阴活检感染并发症风险因素多变量逻辑回归分析

最后,研究人员指出。糖尿病和尿潴留病史的患者更容易在经会阴前列腺活检后发生感染并发症。

原始出处:

Xue-Fei Ding , Yang Luan , Sheng-Ming Lu et al. Risk factors for infection complications after transrectal ultrasound-guided transperineal prostate biopsy. World J Urol. Sep 2020

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1813483, encodeId=4e831813483a8, content=<a href='/topic/show?id=0ba692e7473' target=_blank style='color:#2F92EE;'>#超声引#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92774, encryptionId=0ba692e7473, topicName=超声引)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Sat Dec 19 07:53:08 CST 2020, time=2020-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046043, encodeId=52d3204604375, content=<a href='/topic/show?id=e5713251390' target=_blank style='color:#2F92EE;'>#前列腺活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32513, encryptionId=e5713251390, topicName=前列腺活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Mon Nov 23 05:53:08 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769832, encodeId=09971e698325f, content=<a href='/topic/show?id=b3fc92e7516' target=_blank style='color:#2F92EE;'>#超声引导#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92775, encryptionId=b3fc92e7516, topicName=超声引导)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d66e38113145, createdName=guoyibin, createdTime=Wed Jan 13 15:53:08 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758287, encodeId=30241e58287d4, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Mar 08 19:53:08 CST 2021, time=2021-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278205, encodeId=fef012e8205fd, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Oct 04 08:53:08 CST 2020, time=2020-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513690, encodeId=13cb151369094, content=<a href='/topic/show?id=1a4825835c5' target=_blank style='color:#2F92EE;'>#会阴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25835, encryptionId=1a4825835c5, topicName=会阴)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=769010584396, createdName=ms5439512287675881, createdTime=Sun Oct 04 08:53:08 CST 2020, time=2020-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529281, encodeId=b72d1529281e1, content=<a href='/topic/show?id=6eb91008e03b' target=_blank style='color:#2F92EE;'>#风险因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100870, encryptionId=6eb91008e03b, topicName=风险因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2d411920658, createdName=cenghis, createdTime=Sun Oct 04 08:53:08 CST 2020, time=2020-10-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1813483, encodeId=4e831813483a8, content=<a href='/topic/show?id=0ba692e7473' target=_blank style='color:#2F92EE;'>#超声引#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92774, encryptionId=0ba692e7473, topicName=超声引)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Sat Dec 19 07:53:08 CST 2020, time=2020-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046043, encodeId=52d3204604375, content=<a href='/topic/show?id=e5713251390' target=_blank style='color:#2F92EE;'>#前列腺活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32513, encryptionId=e5713251390, topicName=前列腺活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Mon Nov 23 05:53:08 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769832, encodeId=09971e698325f, content=<a href='/topic/show?id=b3fc92e7516' target=_blank style='color:#2F92EE;'>#超声引导#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92775, encryptionId=b3fc92e7516, topicName=超声引导)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d66e38113145, createdName=guoyibin, createdTime=Wed Jan 13 15:53:08 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758287, encodeId=30241e58287d4, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Mar 08 19:53:08 CST 2021, time=2021-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278205, encodeId=fef012e8205fd, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Oct 04 08:53:08 CST 2020, time=2020-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513690, encodeId=13cb151369094, content=<a href='/topic/show?id=1a4825835c5' target=_blank style='color:#2F92EE;'>#会阴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25835, encryptionId=1a4825835c5, topicName=会阴)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=769010584396, createdName=ms5439512287675881, createdTime=Sun Oct 04 08:53:08 CST 2020, time=2020-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529281, encodeId=b72d1529281e1, content=<a href='/topic/show?id=6eb91008e03b' target=_blank style='color:#2F92EE;'>#风险因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100870, encryptionId=6eb91008e03b, topicName=风险因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2d411920658, createdName=cenghis, createdTime=Sun Oct 04 08:53:08 CST 2020, time=2020-10-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1813483, encodeId=4e831813483a8, content=<a href='/topic/show?id=0ba692e7473' target=_blank style='color:#2F92EE;'>#超声引#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92774, encryptionId=0ba692e7473, topicName=超声引)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Sat Dec 19 07:53:08 CST 2020, time=2020-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046043, encodeId=52d3204604375, content=<a href='/topic/show?id=e5713251390' target=_blank style='color:#2F92EE;'>#前列腺活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32513, encryptionId=e5713251390, topicName=前列腺活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Mon Nov 23 05:53:08 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769832, encodeId=09971e698325f, content=<a href='/topic/show?id=b3fc92e7516' target=_blank style='color:#2F92EE;'>#超声引导#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92775, encryptionId=b3fc92e7516, topicName=超声引导)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d66e38113145, createdName=guoyibin, createdTime=Wed Jan 13 15:53:08 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758287, encodeId=30241e58287d4, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Mar 08 19:53:08 CST 2021, time=2021-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278205, encodeId=fef012e8205fd, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Oct 04 08:53:08 CST 2020, time=2020-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513690, encodeId=13cb151369094, content=<a href='/topic/show?id=1a4825835c5' target=_blank style='color:#2F92EE;'>#会阴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25835, encryptionId=1a4825835c5, topicName=会阴)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=769010584396, createdName=ms5439512287675881, createdTime=Sun Oct 04 08:53:08 CST 2020, time=2020-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529281, encodeId=b72d1529281e1, content=<a href='/topic/show?id=6eb91008e03b' target=_blank style='color:#2F92EE;'>#风险因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100870, encryptionId=6eb91008e03b, topicName=风险因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2d411920658, createdName=cenghis, createdTime=Sun Oct 04 08:53:08 CST 2020, time=2020-10-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1813483, encodeId=4e831813483a8, content=<a href='/topic/show?id=0ba692e7473' target=_blank style='color:#2F92EE;'>#超声引#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92774, encryptionId=0ba692e7473, topicName=超声引)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Sat Dec 19 07:53:08 CST 2020, time=2020-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046043, encodeId=52d3204604375, content=<a href='/topic/show?id=e5713251390' target=_blank style='color:#2F92EE;'>#前列腺活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32513, encryptionId=e5713251390, topicName=前列腺活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Mon Nov 23 05:53:08 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769832, encodeId=09971e698325f, content=<a href='/topic/show?id=b3fc92e7516' target=_blank style='color:#2F92EE;'>#超声引导#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92775, encryptionId=b3fc92e7516, topicName=超声引导)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d66e38113145, createdName=guoyibin, createdTime=Wed Jan 13 15:53:08 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758287, encodeId=30241e58287d4, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Mar 08 19:53:08 CST 2021, time=2021-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278205, encodeId=fef012e8205fd, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Oct 04 08:53:08 CST 2020, time=2020-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513690, encodeId=13cb151369094, content=<a href='/topic/show?id=1a4825835c5' target=_blank style='color:#2F92EE;'>#会阴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25835, encryptionId=1a4825835c5, topicName=会阴)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=769010584396, createdName=ms5439512287675881, createdTime=Sun Oct 04 08:53:08 CST 2020, time=2020-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529281, encodeId=b72d1529281e1, content=<a href='/topic/show?id=6eb91008e03b' target=_blank style='color:#2F92EE;'>#风险因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100870, encryptionId=6eb91008e03b, topicName=风险因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2d411920658, createdName=cenghis, createdTime=Sun Oct 04 08:53:08 CST 2020, time=2020-10-04, status=1, ipAttribution=)]
    2021-03-08 丁鹏鹏
  5. [GetPortalCommentsPageByObjectIdResponse(id=1813483, encodeId=4e831813483a8, content=<a href='/topic/show?id=0ba692e7473' target=_blank style='color:#2F92EE;'>#超声引#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92774, encryptionId=0ba692e7473, topicName=超声引)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Sat Dec 19 07:53:08 CST 2020, time=2020-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046043, encodeId=52d3204604375, content=<a href='/topic/show?id=e5713251390' target=_blank style='color:#2F92EE;'>#前列腺活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32513, encryptionId=e5713251390, topicName=前列腺活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Mon Nov 23 05:53:08 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769832, encodeId=09971e698325f, content=<a href='/topic/show?id=b3fc92e7516' target=_blank style='color:#2F92EE;'>#超声引导#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92775, encryptionId=b3fc92e7516, topicName=超声引导)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d66e38113145, createdName=guoyibin, createdTime=Wed Jan 13 15:53:08 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758287, encodeId=30241e58287d4, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Mar 08 19:53:08 CST 2021, time=2021-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278205, encodeId=fef012e8205fd, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Oct 04 08:53:08 CST 2020, time=2020-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513690, encodeId=13cb151369094, content=<a href='/topic/show?id=1a4825835c5' target=_blank style='color:#2F92EE;'>#会阴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25835, encryptionId=1a4825835c5, topicName=会阴)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=769010584396, createdName=ms5439512287675881, createdTime=Sun Oct 04 08:53:08 CST 2020, time=2020-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529281, encodeId=b72d1529281e1, content=<a href='/topic/show?id=6eb91008e03b' target=_blank style='color:#2F92EE;'>#风险因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100870, encryptionId=6eb91008e03b, topicName=风险因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2d411920658, createdName=cenghis, createdTime=Sun Oct 04 08:53:08 CST 2020, time=2020-10-04, status=1, ipAttribution=)]
    2020-10-04 smlt2008
  6. [GetPortalCommentsPageByObjectIdResponse(id=1813483, encodeId=4e831813483a8, content=<a href='/topic/show?id=0ba692e7473' target=_blank style='color:#2F92EE;'>#超声引#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92774, encryptionId=0ba692e7473, topicName=超声引)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Sat Dec 19 07:53:08 CST 2020, time=2020-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046043, encodeId=52d3204604375, content=<a href='/topic/show?id=e5713251390' target=_blank style='color:#2F92EE;'>#前列腺活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32513, encryptionId=e5713251390, topicName=前列腺活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Mon Nov 23 05:53:08 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769832, encodeId=09971e698325f, content=<a href='/topic/show?id=b3fc92e7516' target=_blank style='color:#2F92EE;'>#超声引导#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92775, encryptionId=b3fc92e7516, topicName=超声引导)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d66e38113145, createdName=guoyibin, createdTime=Wed Jan 13 15:53:08 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758287, encodeId=30241e58287d4, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Mar 08 19:53:08 CST 2021, time=2021-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278205, encodeId=fef012e8205fd, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Oct 04 08:53:08 CST 2020, time=2020-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513690, encodeId=13cb151369094, content=<a href='/topic/show?id=1a4825835c5' target=_blank style='color:#2F92EE;'>#会阴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25835, encryptionId=1a4825835c5, topicName=会阴)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=769010584396, createdName=ms5439512287675881, createdTime=Sun Oct 04 08:53:08 CST 2020, time=2020-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529281, encodeId=b72d1529281e1, content=<a href='/topic/show?id=6eb91008e03b' target=_blank style='color:#2F92EE;'>#风险因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100870, encryptionId=6eb91008e03b, topicName=风险因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2d411920658, createdName=cenghis, createdTime=Sun Oct 04 08:53:08 CST 2020, time=2020-10-04, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1813483, encodeId=4e831813483a8, content=<a href='/topic/show?id=0ba692e7473' target=_blank style='color:#2F92EE;'>#超声引#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92774, encryptionId=0ba692e7473, topicName=超声引)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Sat Dec 19 07:53:08 CST 2020, time=2020-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046043, encodeId=52d3204604375, content=<a href='/topic/show?id=e5713251390' target=_blank style='color:#2F92EE;'>#前列腺活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32513, encryptionId=e5713251390, topicName=前列腺活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Mon Nov 23 05:53:08 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769832, encodeId=09971e698325f, content=<a href='/topic/show?id=b3fc92e7516' target=_blank style='color:#2F92EE;'>#超声引导#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92775, encryptionId=b3fc92e7516, topicName=超声引导)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d66e38113145, createdName=guoyibin, createdTime=Wed Jan 13 15:53:08 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758287, encodeId=30241e58287d4, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Mar 08 19:53:08 CST 2021, time=2021-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278205, encodeId=fef012e8205fd, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Oct 04 08:53:08 CST 2020, time=2020-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513690, encodeId=13cb151369094, content=<a href='/topic/show?id=1a4825835c5' target=_blank style='color:#2F92EE;'>#会阴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25835, encryptionId=1a4825835c5, topicName=会阴)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=769010584396, createdName=ms5439512287675881, createdTime=Sun Oct 04 08:53:08 CST 2020, time=2020-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529281, encodeId=b72d1529281e1, content=<a href='/topic/show?id=6eb91008e03b' target=_blank style='color:#2F92EE;'>#风险因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100870, encryptionId=6eb91008e03b, topicName=风险因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2d411920658, createdName=cenghis, createdTime=Sun Oct 04 08:53:08 CST 2020, time=2020-10-04, status=1, ipAttribution=)]

相关资讯

盘点:前列腺疾病近期进展

前列腺是男性生殖器附属腺中最大的实质性器官。由前列腺组织和肌组织构成。前列腺炎是指由多种复杂原因引起的,以尿道刺激症状和慢性盆腔疼痛为主要临床表现的前列腺疾病。前列腺炎是泌尿外科的常见病,在泌尿外科5

2.6亿!海思科转让前列腺癌新药权益给海创药业

9月7日,海思科发布公告称其子公司四川海思科制药有限公司于9月4日与成都海创药业有限公司签订了《专利实施许可协议及相关协议之解除协议》,海思科将原获授的 HC-1119 及以其为活性成分的各种药物制剂

Sci Rep:不同程度肥胖患者根治性前列腺切除术后生化复发的风险因子差异分析

最近,有研究人员评估了通过肥胖程度分层的患者中,在根治性前列腺切除术后生化复发(BCR)风险因子的差异情况,并关注了使用的手术方法。

Eur Urol:考虑进行前列腺手术男性的下尿路症状诊断评估

前列腺手术能通过减轻膀胱出口梗阻(BOO)来改善下尿路症状(LUTS)。然而,在没有BOO或者逼尿肌活动低下的情况下手术的效果一般。尿动力学(UDS)能够对BOO进行鉴定,且还能测量逼尿肌活性,但是在

Eur Urol:经会阴部间质激光消融:一种对良性前列腺梗阻的新型微创治疗选择

在良性前列腺梗阻(BPO)的治疗中,手术治疗与药物治疗相比其侵袭性陡然增加。最近,人们对微创疗法产生了浓厚的兴趣。最近经会阴间质激光消融(TPLA)被提出用于BPO的治疗。在近期发表在Eur Urol

Prostate Cancer P D:通过CRISPR失活CDKN2A位点和端粒酶的表达实现人原代前列腺上皮细胞永生化

在没有DNA肿瘤病毒蛋白或p16INK4A敲除的情况下,仅用hTERT表达的原代前列腺上皮细胞(PrEC)永生化效率非常低。